Catecholaminergic polymorphic ventricular tachycardia

被引：2
作者：
Frommeyer G. [1 ]
Pott C. [1 ]
Eckardt L. [1 ]
Schulze-Bahr E. [2 ]
机构：
[1] Abteilung Fur Rhythmologie, Department Fur Kardiologie und Angiologie, Universitatsklinikum Munster
[2] Institut Fur Genetik von Herzerkrankungen (IfGH), Department Fur Kardiologie und Angiologie, Universitatsklinikum Munster
来源：
Herzschrittmachertherapie + Elektrophysiologie | 2012年 / 23卷 / 3期
关键词：
A-Blocker therapy; Catecholaminergic polymorphic ventricular tachycardia; Flecainide; Implantable cardioverter-defibrillator; Sudden cardiac death;
D O I：
10.1007/s00399-012-0224-8
中图分类号：
学科分类号：
摘要：
Catecholaminergic polymorphic ventricular tachycardia (PCVT) is a rare, congenital ventricular tachyarrhythmia which occurs in the setting of adrenergic activation. It potentially leads to syncope and/or sudden cardiac death (SCD). PCVT represents one of the most dangerous congenital ion channel diseases. Mutations of the ryanodine receptor gene (RYR2), the calsequestrin gene (CASQ2), and the triadin gene (TRDN) have been identified as an underlying correlate. a-Blockers are employed as therapy and are sometimes combined with class IC antiarrhythmic drugs, or calcium antagonists of the verapamil type. ICD implantation is recommended in case of persisting syncope in the presence of a-blocker therapy or survived SCD. Left thoracic sympathectomy represents a subsidiary interventional therapy for individual cases. In addition, modifications of the patients lifestyle including avoidance of physical stress and heart rates > 120/min are recommended. © Springer-Verlag 2012."
引用
收藏
页码：231 / 236
页数：5
相关论文
共 30 条
[1]  
Pflaumer A., Davis A.M., Guidelines for the diagnosis and management of catecholaminergic polymorphic ventricular tachycardia, Heart Lung Circ, 21, pp. 96-100, (2012)
[2]  
Leenhardt A., Lucet V., Denjoy I., Grau F., Ngoc D.D., Coumel P., Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year followup of 21 patients, Circulation, 91, pp. 1512-1519, (1995)
[3]  
Priori S.G., Napolitano C., Memmi M., Colombi B., Drago F., Gasparini M., Desimone L., Coltorti F., Bloise R., Keegan R., Cruz Filho F.E., Vignati G., Benatar A., De- Logu A., Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia, Circulation, 106, pp. 69-74, (2002)
[4]  
Sumitomo N., Harada K., Nagashima M., Yasuda T., Nakamura Y., Aragaki Y., Saito A., Kurosaki K., Jouo K., Koujiro M., Konishi S., Matsuoka S., Oono T., Hayakawa S., Miura M., Ushinohama H., Shibata T., Niimura I., Catecholaminergic polymorphic ventricular tachycardia: Electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death, Heart, 89, pp. 66-70, (2003)
[5]  
Hayashi M., Denjoy I., Extramiana F., Maltret A., Buisson N.R., Lupoglazoff J.M., Klug D., Takatsuki S., Villain E., Kamblock J., Messali A., Guicheney P., Lunardi J., Leenhardt A., Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia, Circulation, 119, pp. 2426-2434, (2009)
[6]  
Tester D.J., Arya P., Will M., Haglund C.M., Farley A.L., Makielski J.C., Ackerman M.J., Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing, Heart Rhythm, 3, pp. 800-805, (2006)
[7]  
Priori S.G., Napolitano C., Tiso N., Memmi M., Vignati G., Bloise R., Sorrentino V., Danieli G.A., Mutations in the cardiac ryanodine receptor gene (hryr2) underlie catecholaminergic polymorphic ventricular tachycardia, Circulation, 103, pp. 196-200, (2001)
[8]  
Lahat H., Pras E., Olender T., Avidan N., Ben-Asher E., Man O., Levy-Nissenbaum E., Khoury A., Lorber A., Goldman B., Lancet D., Eldar M., A missense mutation in a highly conserved region of casq2 is associated with autosomal recessive catecholamine- induced polymorphic ventricular tachycardia in bedouin families from israel, Am J Hum Genet, 69, pp. 1378-1384, (2001)
[9]  
Roux-Buisson N., Cacheux M., Fourest-Lieuvin A., Fauconnier J., Brocard J., Denjoy I., Durand P., Guicheney P., Kyndt F., Leenhardt A., Le Marec H., Lucet V., Mabo P., Probst V., Monnier N., Ray P.F., Santoni E., Tremeaux P., Lacampagne A., Faure J., Lunardi J., Marty I., Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human, Hum Mol Genet, 21, pp. 2759-2767, (2012)
[10]  
Ackerman M.J., Priori S.G., Willems S., Berul C., Brugada R., Calkins H., Camm A.J., Ellinor P.T., Gollob M., Hamilton R., Hershberger R.E., Judge D.P., Le Marec H., McKenna W.J., Schulze-Bahr E., Semsarian C., Towbin J.A., Watkins H., Wilde A., Wolpert C., Zipes D.P., Hrs/ehra expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: This document was developed as a partnership between the heart rhythm society (hrs) and the european heart rhythm a
123